CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more
CureVac AG said Deputy Chairman Jean Stéphenne will become chairman. He is the former president and chairman of the biologicals unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). It's another management change for the biotech as it moves forward with its COVID-19 mRNA vaccine. Deputy CEO Franz-Werner Haas took over as CEO in March, just five days after Ingmar Hoerr replaced Daniel Menichella as CEO. Also last month, CureVac received an €80 million ($88.0 million) EIB loan to expand its COVID-19 manufacturing capacity (see "CureVac CEO Hoerr Takes Leave of Absence").
Susan Desmond-Hellmann has joined the board of Pfizer Inc. (NYSE:PFE). She stepped down as CEO of the Bill & Melinda Gates Foundation in December, and previously, she spent 14 years at Genentech Inc. She also served as the first female chancellor of the University of California at San Francisco in 2009-14...